Kallyope Gains $112M to Move “Gut-Brain Axis” Programs to the Clinic
Summary
Kallyope (pronounced Kahl-EE-oh-pay) on Wednesday revealed its lead drug is designed to target satiety circuits, or the pathways that play a role in the feeling of fullness, to reduce the weight of patients with obesity. The fresh cash is slated to keep the company humming for three years, providing enough funding to get the obesity treatment into the clinic, as well as the second-most advanced program in its lineup, which targets gut barrier function. Waltham, MA-based Axial Biotherapeutics, which launched in 2016 with a $19 million Series A financing round, last summer dosed the first patient in a Phase 1b/2a trial of an investigational drug designed to ameliorate GI and behavioral symptoms in people with autism spectrum disorder. When Kallopye first launched, it planned to develop therapeutics and consumer products, but has since narrowed its focused to small molecules that can block or boost the signals that run between the gut and the rest of the body. The biotech was started by a trio of Columbia University professors: Lasker Award winner Tom Maniatis, Nobel laureate Richard Axel, and Charles Zuker, the latter two who are well known for their research into how the brain interprets smell and taste.
Funding
Review available funding amount, funding date, investors, and linked company information related to Kallyope Gains $112M to Move “Gut-Brain Axis” Programs to the Clinic in the interactive ISVWorld profile.
Classifications
AskAI Classifications
LabelsLinked Companies
